Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials

Diana S Meske1
Oluwadolapo D Lawal1
Harrison Elder1
Valerie Langberg2
Florence Paillard1
Nathaniel Katz1,3

1Analgesic Solutions, Natick, MA, USA, 2The Center for Evidence Synthesis in Health, Brown University, Providence, RI, USA, 3Department of Anesthesiology and Perioperative Medicine, Tufts University School of Medicine, Boston, MA, USA

Introduction: Opioids have been used for millennia for the treatment of pain. However, the long-term efficacy of opioids to treat chronic non-cancer pain continues to be debated. To evaluate opioids’ efficacy in chronic non-cancer pain, we performed a meta-analysis of published clinical trials for μ-opioid receptor agonists performed for US Food and Drug Administration approval.

Methods: MEDLINE and Cochrane trial register were searched for enriched enrollment randomized withdrawal studies (before June 2016). Selection criteria included: adults, ≥10 subjects per arm, any chronic pain condition, double-blind treatment period lasting ≥12 weeks, and all μ-agonist opioids approved in the USA.

Results: Fifteen studies met criteria. Opioid efficacy was statistically significant (p<0.001) versus placebo for pain intensity (standardized mean difference: −0.416), ≥30% and ≥50% improvement in pain (risk difference: 0.166 and 0.137), patient global impression of change (0.163), and patient global assessment of study medication (0.194). There were minor benefits on physical function and no effect on mental function.

Conclusion: Opioids are efficacious in the treatment of chronic non-cancer pain for up to 3 months in randomized controlled trials. This should be considered, alongside data on opioid safety, in the use of opioids for the treatment of chronic pain.

Keywords: opioid analgesics, non-cancer pain, long-term efficacy, EERW trials, opioid efficacy; evidence-based medicine

Introduction

Opioids have been used for millennia for the treatment of pain and remain an important therapeutic option. While the American Academy of Pain Medicine, the American Pain Society, the US Federation of State Medical Boards, and the Centers for Disease Control and Prevention endorse the use of opioids, when appropriate, for the treatment of chronic pain, efficacy of long-term opioid use remains controversial.1–6 In addition, there are significant risks associated with opioids and these agents have contributed to the epidemic of opioid abuse, addiction, and overdose deaths in the USA.7–10 Given these serious risks, the assessment of evidence for the long-term analgesic efficacy of opioids for treating chronic pain is crucial.

The US Food and Drug Administration (FDA) requires randomized, double-blind, placebo-controlled studies of at least 3 months’ duration in order to approve an opioid for the treatment of chronic pain. This reflects the need to balance accrual of sufficient data representative of long-term treatment against the scientific and ethical challenges of longer-term randomized, placebo-controlled trials, including dropouts, missing data, concomitant treatments, and long-term use of placebo. The 3-month duration is
the standard clinical trial duration accepted by the FDA for many chronic conditions including hypertension, asthma, depression, schizophrenia, bipolar disorder, and anxiety.

In order to inform the ongoing controversy over whether there is evidence that opioids are efficacious for the treatment of chronic pain, we have gathered the randomized controlled trials required by the FDA for approval, and have performed a meta-analysis of their results. These trials are by regulatory expectation 3 months in duration. This review does not address the risks of opioids. A coherent position on the risk–benefit balance of opioids for the treatment of chronic pain requires an accurate and data-driven assessment of both their risks and their benefits. Thus, the purpose of this review is not to minimize, or characterize, the risks of opioids, but rather to ensure that the debate over the risks and benefits of opioids is informed by an accurate assessment of their benefits.

Methods

Data sources and searches

MEDLINE and Cochrane Central Register of Controlled Trials 2012 were searched for all relevant studies published before June 2016. The search strategy for MEDLINE is presented (see Methods in Supplementary materials) and was customized for the Cochrane Central Register of Controlled Trials 2012 (in which only the Intervention and Population sections were used). Additional studies were identified through the examination of references from identified trials, systematic reviews, and authors’ own databases.

We searched for enriched enrollment randomized withdrawal (EERW) studies published in English with double-blinded outcome assessments that compared any opioid (including combinations and dual mechanism analgesics administered via the oral, transdermal, nasal, sublingual, or transmucosal routes) to placebo for ≥12 weeks during the randomized double-blind treatment phase of the study in patients with any chronic non-malignant pain condition.

Study selection

Inclusion and exclusion criteria

Trials with participants ≥18 years of age with any type of chronic nonmalignant pain, including but not limited to chronic low back pain (CLBP), chronic neuropathic pain, diabetic peripheral neuropathic pain (DPNP), osteoarthritis (OA), arthritis, rheumatoid arthritis, phantom limb pain, fibromyalgia, post-herpetic neuralgia, or musculoskeletal pain. Studies of acute or post-surgical pain and cancer pain were excluded. Studies of specific μ-agonist opioids, μ-agonist opioids with additional pharmacological activity (eg, tramadol and tapentadol), or combination opioids (eg, hydrocodone/acetaminophen) approved for the treatment of pain were included. Agents with oral, transdermal, nasal, sublingual, or transmucosal routes of administration were included. Studies were included if they had a minimum of 10 patients per arm and reported pain intensity (PI) as an outcome. The present study protocol has been published on PROSPERO (http://www.crd.york.ac.uk/PROSPERO; registration No: CRD42015026378).

Selection methodology

Two authors independently screened titles and abstracts using the Abstrackr software to identify manuscripts that met the abovementioned inclusion criteria. Full-text articles were obtained for manuscripts that appeared to meet the inclusion criteria or were likely to meet the inclusion criteria. The full text of these manuscripts was read to determine final inclusion in the meta-analysis. Any disagreement on manuscript inclusion was resolved through discussion among the authors.

Data extraction and quality assessment

Data extraction methodology

Two authors independently extracted data from each manuscript using the Systematic Review Data Repository (SRDR) form (http://srdr.ahrq.gov/; retrieved: June 1 2016). A third author subsequently confirmed that primary and secondary endpoints matched the SRDR form. The SRDR is an open collaborative web-based repository for systematic data review. The SRDR form was developed to include participant characteristics, interventions, treatment arms, adverse events (AEs), primary and secondary outcomes, country(s) of study, number of study sites, trial design, blinding, clinical setting, method of recruitment, group similarities at baseline, and assessment bias. If data were not available or incomplete, manuscript authors were contacted to provide the missing data.

Quality assessment

Risk of bias was assessed based on the guidelines available through the Cochrane Risk of Bias Tool of the SRDR (http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm). We defined high-quality studies (ie, low bias studies) as those with no major methodological flaws that fulfilled 6 or more of the 11 internal validity criteria.

Data extracted

The following outcome measures were extracted from the selected publications: change in PI score from randomization...
baseline to week 12 or study endpoint, categorical evaluation of responders/non-responders (≥30% and ≥50% improvement as calculated based on changes between week 12 and pain at the beginning of the open-label titration phase), patient assessments of global improvement (eg, patient global impression of pain [PGIC] and patient global assessment of study medication [PGASM]), assessment of patient change in function (eg, Roland–Morris Disability Questionnaire [RMDQ] and Western Ontario and McMaster Universities Arthritis Index [WOMAC]), rescue medication dose consumption, and health-related quality of life (eg, 36-Item Short-Form Survey [SF-36]).

Safety outcomes collected included: the proportion of patients with ≥1 AE, ≥1 serious AE (SAE), discontinuing treatment due to AEs and/or withdrawal symptoms post-randomization; AEs during the open-label titration phase were not collected.

Data synthesis and analysis
The primary outcome was standardized effect size, defined as the treatment difference (mean difference in PI score between active and placebo) divided by the SD. We pooled data from all manuscripts regardless of whether the endpoint was presented as mean change from randomization baseline to week 12 or as the least squares mean difference (LSMD) at week 12; if both results were available, the mean change from randomization baseline to week 12 was used. The mean change from baseline was calculated from the reported mean baseline and week 12 data; the SD of the change was calculated by assuming a correlation of 0.50 between baseline and week 12 responses. The standard mean difference (SMD) was calculated with 95% CIs. The change in PI from randomization baseline to week 12 was reported as the LSMD and standard error (SE); in case SD or SE were not available, they were calculated based on the following formula: SE = SD/square root (N). When SD values were not available, the manuscript authors were contacted. We were able to obtain all unpublished SD values. The number of subjects randomized was used in all analyses except in situations where a different N value was more appropriate to use (eg, some manuscripts did not present data for 100% of patients in PGIC tables; in this situation, we calculated the total number of patients randomized based on the percentage of reporting patients).

A binary random-effects meta-analysis using the restricted maximum likelihood method was conducted to assess ≥30% and ≥50% responder rates. The results are reported as risk differences (RDs). The same approach was used for PGIC results (combining “very much improved” and “much improved” responses) and PGASM (combining “excellent” and “very good” results). Function endpoints were not reported in all manuscripts, and for manuscripts that did report function endpoints, a variety of different measures were used (RMDQ, WOMAC, and Oswestry Disability Index). Therefore, no meta-analysis was performed; instead, these data were presented in a tabular format. Quality of life measures (mean change from baseline to week 12; SF-36 or SF-12v2) were combined and a meta-analysis was conducted using a linear regression model. The numbers of patients who discontinued treatment due to an AE were subjected to a binary random-effects meta-analysis using the restricted maximum likelihood method. The results are presented as RDs. In order to assess the percent of patients who benefited from the study drug, a weighted mean was calculated for the percentage of patients who met inclusion criteria (ie, found the study drug both efficacious and tolerable) and were randomized to the randomized double-blind treatment phase. The statistical analysis was performed using the OpenMetaAnalyst Software.13

Meta-analysis findings
A total of 2,018 references were identified from our search; of these, 26 full-text articles were obtained for screening and 15 met our inclusion criteria (Figure 1).14–28

Figure 1 Study flow diagram.
Included studies
A summary of the characteristics of EERW trials included in the meta-analysis is presented in Table 1 and Table S1. Fourteen of the 15 studies were considered high-quality studies (having low bias; Table S2). Hydrocodone was evaluated in 4 trials; oxymorphone, oxycodone, buprenorphine and tapentadol in 2 trials each; and hydromorphone, morphine/naltrexone, and tramadol in 1 trial each. CLBP was evaluated in 10 studies, DPNP in 2 studies, OA in 2 studies, and 1 study evaluated a combination of CLBP and OA patients.

Study design
All included studies were randomized, double-blind, placebo-controlled EERW studies as defined by the literature search inclusion criteria. All included studies used a parallel group design during the randomized double-blind treatment phase. In 13 of the 15 trials, patients were initially titrated to an individualized effective dose and then either allowed to continue their individualized dose or randomized to the placebo group during the randomized double-blind treatment phase. In 1 trial, all patients were titrated to the highest dose of the study drug and subsequently randomized to a high-dose group, a low-dose group, or the placebo group. In another trial, all patients were allowed to adjust the titrated dose after randomization for the first 4 weeks and then the dose was fixed for the next 8 weeks.

The open-label titration phase lasted between 2 and 8 weeks and the randomized double-blind treatment phase lasted 12 weeks for all studies (Table 1). Most studies made

Table 1 Study design and subject disposition by study

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Drug, pain type</th>
<th>No of sites, Countries</th>
<th>Opioid naive patients, n (%)</th>
<th>Patients enrolled in the OLP, n</th>
<th>Discontinued during OLP, %</th>
<th>OLP duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hale et al,27 2015</td>
<td>Hydrocodone ER, CLBP</td>
<td>66, USA</td>
<td>0 (0)</td>
<td>251</td>
<td>43</td>
<td>Up to 1 month</td>
</tr>
<tr>
<td>Katz et al,26 2015</td>
<td>Oxymorphone ER, CLBP</td>
<td>30, USA</td>
<td>0 (0)</td>
<td>286</td>
<td>37</td>
<td>Up to 1 month</td>
</tr>
<tr>
<td>Vorsanger et al,23 2008</td>
<td>Tramadol ER, CLBP</td>
<td>30, USA</td>
<td>Not stated</td>
<td>619</td>
<td>38</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Hale et al,23 2010</td>
<td>OROS Hydrocodone ER, CLBP</td>
<td>61, USA</td>
<td>Not stated</td>
<td>547</td>
<td>37</td>
<td>Up to 45 days</td>
</tr>
<tr>
<td>Katz et al,22 2010</td>
<td>EMBEDA; MS-sNT (morphine sulfate and naltrexone hydrochloride ER capsules), OA</td>
<td>Not stated, USA</td>
<td>254 (73.8)</td>
<td>547</td>
<td>37</td>
<td>Up to 45 days</td>
</tr>
<tr>
<td>Schwartz et al,23 2011</td>
<td>Tapentadol ER, DPNP</td>
<td>93, USA and Canada</td>
<td>255 (65.5)</td>
<td>588</td>
<td>33</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Friedmann et al,21 2011</td>
<td>Remoxy (Oxycodone ER), OA</td>
<td>61, USA</td>
<td>Not stated</td>
<td>558</td>
<td>26</td>
<td>2 weeks</td>
</tr>
<tr>
<td>Steiner et al,14 2011</td>
<td>Buprenorphine transdermal system (BTDS), CLBP</td>
<td>86, USA</td>
<td>541 (100)</td>
<td>1024</td>
<td>47</td>
<td>Up to 27 days</td>
</tr>
<tr>
<td>Rauck et al,24 2014</td>
<td>Zohydro (Hydrocodone ER), CLBP</td>
<td>59, USA</td>
<td>0 (0)</td>
<td>510</td>
<td>41</td>
<td>Up to 6 weeks</td>
</tr>
<tr>
<td>Vink et al,23 2014</td>
<td>Tapentadol ER, DPNP</td>
<td>80, USA and Canada</td>
<td>218 (68.5)</td>
<td>459</td>
<td>22</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Wen et al,17 2015</td>
<td>Hysingla ER (Hydrocodone bitartrate ER), CLBP</td>
<td>102, USA and Canada</td>
<td>329 (56)</td>
<td>905</td>
<td>35</td>
<td>Up to 45 days</td>
</tr>
<tr>
<td>Katz et al,14 2015</td>
<td>Xtampa ER (Oxycodone ER), CLBP</td>
<td>46, USA</td>
<td>192 (49.3)</td>
<td>740</td>
<td>47</td>
<td>Up to 6 weeks</td>
</tr>
<tr>
<td>Hale et al,15 2015</td>
<td>Hydrocodone ER, CLBP/OA</td>
<td>71, USA</td>
<td>147 (50)</td>
<td>389</td>
<td>24</td>
<td>Up to 6 weeks</td>
</tr>
<tr>
<td>Hale et al,17 2015</td>
<td>Hydrocodone ER, CLBP</td>
<td>78, USA</td>
<td>215 (58)</td>
<td>625</td>
<td>41</td>
<td>Up to 6 weeks</td>
</tr>
<tr>
<td>Rauck et al,26 2016</td>
<td>Buccal buprenorphine, CLBP</td>
<td>60, USA</td>
<td>420 (100)</td>
<td>749</td>
<td>39</td>
<td>Up to 8 weeks</td>
</tr>
</tbody>
</table>

Notes: *Number of sites initiated. aConcomitant analgesics were not allowed during the dose titration. The paper does not state anything about concomitant analgesics for the period following this.

Abbreviations: CLBP, chronic low back pain; DPNP, diabetic peripheral neuropathic pain; ER, extended release; OA, osteoarthritis; OLP, open label phase; RBTP, randomized blinded treatment phase.
efforts to prevent or reduce discontinuation of patients randomized to the placebo group in the randomized double-blind treatment phase by allowing the use of rescue medication (12/15) and/or tapering the opioid in placebo patients (10/15; Table 1). All studies analyzed the intent-to-treat population for primary and secondary outcomes.

### Efficacy

#### Primary endpoint: PI

With regard to primary endpoint measurements, the change from randomization baseline to week 12 was reported by 4 studies as the LSMD,

and by all other studies as the mean change (Table S1). The effect of opioids was statistically significant ($p<0.001$) versus placebo for the change in PI score from randomization baseline to week 12 (SMD = $-0.416$; 95% CI: $-0.521$ to $-0.312$; Figure 2) as assessed by binary random-effects model meta-analysis using the restricted maximum likelihood method. Only 1 study did not report a statistically significant difference versus placebo for the change in area under the curve between drug and placebo, which was the study’s primary endpoint, was statistically significant.

#### Other efficacy endpoints

Responder rates were reported in 12 manuscripts (Tables S3 and S4). However, 2 were excluded since they reported respondent analysis as increment in pain from baseline of the

<table>
<thead>
<tr>
<th>Duration of study drug tapering</th>
<th>Patients randomized in each arm of RBTP, n</th>
<th>RBTP dosing regimen and duration</th>
<th>Post-randomization discontinuations, %</th>
<th>Concomitant analgesics allowed?</th>
<th>Rescue medication allowed?</th>
</tr>
</thead>
</table>
| No taper (4-day extended access to rescue opioid) | Oxycodeone ER: 70
Placebo: 72 | Fixed dose 12 weeks | Oxycodeone ER: 30
Placebo: 76 | No | Yes |
| No taper (4-day extended access to rescue opioid) | Oxycodeone ER: 105
Placebo: 100 | Fixed dose 12 weeks | Oxycodeone ER: 32
Placebo: 53 | No | Yes |
| Not stated | Tramadol ER 300 mg: 127
Placebo: 126 | Adjustable dose 12 weeks | Tramadol ER 300 mg: 33 Placebo: 48 | No | Not stated |
| 2 weeks | Hydromorphone ER: 133
Placebo: 133 | Fixed dose 12 weeks | Hydromorphone ER: 51
Placebo: 68 | No | Yes |
| 2 weeks | MS-sNT: 170
Placebo: 173 | Fixed dose 12 weeks | MS-sNT: 36
Placebo: 43 | No | Yes |
| 3 days | Tapentadol ER: 196
Placebo: 193 | Fixed dose 12 weeks | Tapentadol ER: 32
Placebo: 32 | No | No |
| Up to 15 days | Oxycodeone ER: 203
Placebo: 207 | Adjustable for first 4 weeks then fixed for 8 weeks | Oxycodeone ER: 34
Placebo: 36 | No | Not stated |
| No taper | BTDS: 257
Placebo: 283 | Fixed dose 12 weeks | BTDS: 33
Placebo: 30 | No | Yes |
| 2 weeks | Hydrocodeone ER: 151
Placebo: 151 | Fixed dose 12 weeks | Hydrocodeone ER: 18
Placebo: 61 | No | Yes |
| 3 days | Tapentadol ER: 166
Placebo: 152 | Fixed dose 12 weeks | Tapentadol ER: 28
Placebo: 30 | No | Yes |
| 2 weeks | Hydrocodeone ER: 296
Placebo: 292 | Fixed dose 12 weeks | Hydrocodeone ER: 23
Placebo: 28 | No | Yes |
| Up to 20 days | Xtampa ER: 193
Placebo: 196 | Fixed dose 12 weeks | Xtampa ER: 37
Placebo: 49 | No | Yes |
| 2 weeks | Hydrocodeone ER: 146
Placebo: 147 | Fixed dose 12 weeks | Hydrocodeone ER: 36
Placebo: 31 | Yes | Yes |
| 2 weeks | Hydrocodeone ER: 191
Placebo: 180 | Fixed dose 12 weeks | Hydrocodeone ER: 18
Placebo: 21 | Not stated | Yes |
| No taper | Buccal Buprenorphine: 209
Placebo: 211 | Fixed dose 12 weeks | Buccal Buprenorphine: 24
Placebo: 25 | No | Yes |
blinded period rather than reduction in pain from the baseline at the beginning of the open-label titration phase. A binary random-effects meta-analysis using the restricted maximum likelihood method demonstrated a statistically significant difference between study drug and placebo for both ≥30% (RD estimate [SE]: 0.166 [0.028], p<0.001) and ≥50% (0.173 [0.022], p<0.001) decrease from baseline in PI (Table 2; Figure 3). PGIC was reported in 5 manuscripts,16–18,23,25 (Tables S3 and S4) and meta-analysis combining patients “very much improved” and “much improved” showed a statistically significant difference between study drug and placebo in PGIC (RD estimate [SE]: 0.163 [0.029], p<0.001; Table 2). PGASM was assessed in 5 manuscripts,14,15,19,21,24 (Tables S3 and S4) and meta-analysis combining “excellent” and “very good” response showed a statistically significant difference between study drug and placebo (RD estimate [SE]: 0.137 [0.022], p<0.001; Table 2). Functional outcomes were reported in 5 manuscripts (Tables S3 and S4);18,22,25,27,28 however, a variety of assessment types were reported. Three manuscripts8,27,28 reported RMDQ (mean [SD] change from baseline to week 12; study drug vs placebo: 0.4 [4.83] vs 0.7 [5.32], −1.29 [4.98] vs −1.57 [4.82], and 0.6 [5.37] vs 1.2 [5.72]), 1 manuscript22 reported WOMAC (study drug vs placebo: 1.6 [18.0] vs 5.8 [16.8]), and 1 manuscript22 reported functional outcomes on the Brief Pain Inventory (BPI) scale (study drug vs placebo: −3.0 [2.07] vs −2.6 [2.38]) (Table S3). Due to a low number of manuscripts reporting functional outcome data and the different outcome

### Table 2 Summary of secondary endpoints

<table>
<thead>
<tr>
<th>Secondary endpoint</th>
<th>Study drug vs placebo</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responder rate for ≥30% improvement</td>
<td>0.166 (0.028)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Responder rate for ≥50% improvement</td>
<td>0.137 (0.022)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PGIC (“Very much improved” and “Improved”)</td>
<td>0.163 (0.029)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PGASM (“Excellent” and “Very good”)</td>
<td>0.194 (0.056)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Patients discontinued due to an AE</td>
<td>0.021 (0.008)</td>
<td>0.011</td>
</tr>
</tbody>
</table>

Note: *Values are the risk difference (RD) estimates (SE).

Abbreviations: AE, adverse event; PGASM, patient global assessment of study medication; PGIC, patient global impression of pain; SE, standard error.

### Figure 2
Change in PI from randomization baseline to week 12 with active study opioid drug versus placebo.

Notes: The standardized mean difference effect size was −0.416 and p<0.001, with a lower bound estimate of −0.521 and an upper bound −0.312.

Abbreviation: PI, pain intensity.

### Figure 3
Percentage of patients with ≥30% or ≥50% improvement with active study drug versus placebo.

Notes: The graph shows the mean (SD) percent of patients with improvement, from each study that reported these data. A binary random-effects meta-analysis using the restricted maximum likelihood method was performed showing a statistically significant difference between active study drug and placebo for both ≥30% and ≥50%.
measure used, no meta-analysis was performed. Of these 5 manuscripts reporting functional data, 2 showed a greater improvement in function in the study drug group compared to placebo.22,25 Quality of life data were reported in only 3 manuscripts16,18,25 (Tables S3 and S4); therefore, no meta-analysis was performed. Physical component summary values were greater for study drug than for placebo in all 3 manuscripts (10.11 vs 6.12, 0.1 vs −2.3, and 7.52 vs 3.62), while mental component summary values were greater for study drug versus placebo for 2 manuscripts16,25 (7.19 vs 3.34 and 0.20 vs −0.8; Table S3). No meta-analysis of rescue medication dose consumption was conducted due to insufficient data. The overall weighted mean (SD) of the percentage of patients who were randomized from the open-label titration phase was 63.2% (7.4). Data are presented for each manuscript in Table 1.

### Safety endpoints

Reported AEs and SAEs post-randomization were similar between study drug and placebo in all studies (Table 3). The overall weighted mean discontinuation rate was numerically higher for placebo (42.1%) than study drug (31.0%), and was likely related to discontinuation due to lack of efficacy in the placebo group. There was a small but statistically significant difference in the percentage of patients who discontinued due to an AE in the study drug group versus the placebo group (RD estimate [SE]: 0.021 [0.008], \( p = 0.011 \)). The proportion of patients who discontinued due to SAEs was not included in this analysis because no manuscript reported it. The average rate of discontinuation due to opioid withdrawal was similar between study drug and placebo (Table 3).

### Table 3 Summary of AEs

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study drug/placebo</th>
<th>Patients with ≥1 AE, n (%)</th>
<th>Patients with ≥1 SAE, n (%)</th>
<th>Patients who discontinued due to an AE, n (%)</th>
<th>Patients who discontinued due to opioid withdrawal, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hale et al, 2007</td>
<td>Study drug:</td>
<td>31 (44.3)</td>
<td>2 (2.9)</td>
<td>7 (10.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>27 (37.5)</td>
<td>0 (0.0)</td>
<td>8 (11.1)</td>
<td>5 (6.9)</td>
</tr>
<tr>
<td>Katz et al, 2007</td>
<td>Study drug:</td>
<td>61 (58.1)</td>
<td>2 (1.9)</td>
<td>9 (8.6)</td>
<td>1 (1.0)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>44 (44.0)</td>
<td>3 (3.0)</td>
<td>8 (8.0)</td>
<td>2 (2.0)</td>
</tr>
<tr>
<td>Vorsanger et al, 2008</td>
<td>Study drug:</td>
<td>79 (62.2)</td>
<td>ND</td>
<td>13 (10.2)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>72 (57.1)</td>
<td>ND</td>
<td>18 (14.3)</td>
<td>ND</td>
</tr>
<tr>
<td>Hale et al, 2010</td>
<td>Study drug:</td>
<td>64 (48.1)</td>
<td>1 (0.8)</td>
<td>7 (5.3)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>73 (54.9)</td>
<td>4 (3.0)</td>
<td>3 (2.3)</td>
<td>7 (5.3)</td>
</tr>
<tr>
<td>Katz et al, 2010</td>
<td>Study drug:</td>
<td>91 (53.2)</td>
<td>6 (3.5)</td>
<td>18 (10.6)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>84 (48.6)</td>
<td>3 (1.7)</td>
<td>13 (7.5)</td>
<td>ND</td>
</tr>
<tr>
<td>Schwartz et al, 2011</td>
<td>Study drug:</td>
<td>139 (70.9)</td>
<td>10 (5.1)</td>
<td>22 (11.2)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>100 (51.8)</td>
<td>3 (1.6)</td>
<td>11 (5.7)</td>
<td>ND</td>
</tr>
<tr>
<td>Friedmann et al, 2011</td>
<td>Study drug:</td>
<td>ND</td>
<td>5 (2.4)</td>
<td>43 (21.0)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Steiner et al, 2011</td>
<td>Study drug:</td>
<td>140 (54.5)</td>
<td>3 (1.2)</td>
<td>40 (15.6)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>146 (51.6)</td>
<td>2 (0.7)</td>
<td>20 (7.1)</td>
<td>ND</td>
</tr>
<tr>
<td>Rauck et al, 2014</td>
<td>Study drug:</td>
<td>91 (60.3)</td>
<td>ND</td>
<td>2 (1.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>67 (44.4)</td>
<td>ND</td>
<td>5 (3.3)</td>
<td>7 (4.6)</td>
</tr>
<tr>
<td>Vinik et al, 2014</td>
<td>Study drug:</td>
<td>23 (13.9)</td>
<td>8 (4.8)</td>
<td>19 (11.4)</td>
<td>4 (2.4)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>13 (8.6)</td>
<td>9 (5.9)</td>
<td>12 (7.9)</td>
<td>5 (3.3)</td>
</tr>
<tr>
<td>Wen et al, 2015</td>
<td>Study drug:</td>
<td>136 (45.9)</td>
<td>2 (0.7)</td>
<td>17 (5.7)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>103 (35.3)</td>
<td>4 (1.4)</td>
<td>10 (3.4)</td>
<td>ND</td>
</tr>
<tr>
<td>Katz et al, 2015</td>
<td>Study drug:</td>
<td>125 (64.8)</td>
<td>2 (1.0)</td>
<td>15 (7.8)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>95 (48.5)</td>
<td>2 (1.0)</td>
<td>10 (5.1)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Hale et al, 2015</td>
<td>Study drug:</td>
<td>93 (63.7)</td>
<td>3 (2.1)</td>
<td>9 (6.2)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>95 (48.5)</td>
<td>2 (1.0)</td>
<td>10 (5.1)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Hale et al, 2015</td>
<td>Study drug:</td>
<td>106 (55)</td>
<td>3 (1.6)</td>
<td>11 (5.8)</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>88 (49)</td>
<td>3 (1.7)</td>
<td>7 (3.9)</td>
<td>ND</td>
</tr>
<tr>
<td>Rauck et al, 2016</td>
<td>Study drug:</td>
<td>38 (16.6)</td>
<td>3 (1.4)</td>
<td>13 (5.7)</td>
<td>3 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Placebo:</td>
<td>40 (17.2)</td>
<td>1 (0.5)</td>
<td>7 (3.0)</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

Notes: *Only data for the 300 mg doses of tramadol were used in this meta-analysis.

Abbreviations: AE, adverse event; ND, no data; SAE, serious AE.
Discussion

The recent claims that opioids lack efficacy for chronic pain have created controversy among physicians, prescribers, regulators, scientists, and the general public regarding whether the benefits of opioid use outweigh the public health risks of abuse and other complications.27–30 Chou et al state “evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving pain” based on the opinion that studies of ≤1 year duration do not provide evidence of “long-term” efficacy.31 Clearly if there is no benefit then no amount of risk should be tolerated. This review was, therefore, performed in order to gather together the key evidence to facilitate understanding opioid efficacy within the paradigm of FDA studies required for approval, and to perform a meta-analysis in order to quantify opioid efficacy for chronic pain and assess consistency of effects across studies conducted for ≥2 months’ duration. This meta-analysis was limited to EERW-designed studies, since this design is by far the most commonly utilized for regulatory approval and therefore supports combinability.

Several systematic reviews and meta-analyses regarding the efficacy of opioids in chronic pain have been published; however, these studies were published nearly a decade ago31–33 and the more recent ones are not meta-analyses.4,34,35 Additionally, many studies included in previous reviews are not relevant to our study because they report alternate routes of administration (eg, intravenous),4 have short study durations,31,36 are open-label12,34 or observational studies,35 have restricted pain types,33,36 or compare different study designs.31,33,36 Although most of these meta-analyses concluded that opioids were efficacious for the treatment of chronic non-cancer pain,11–34,36 a review specifically focused on studies designed for FDA approval (ie, of ≥3 months’ duration) for chronic pain has not been done.

The EERW design provides an opportunity to evaluate both “effectiveness” (outcomes in the open-label titration phase) and “efficacy” (outcomes in the randomized, double-blind, placebo-controlled phase). The present meta-analysis demonstrated the “effectiveness” of opioids since a majority of patients (63%) demonstrated a clinically meaningful response. The pharmacological efficacy of opioids for the treatment of chronic pain was evidenced by statistically significant differences between study drug and placebo in change in pain score from randomization to week 12 and in response rates.

With regard to secondary endpoints, opioids were found to marginally improve physical function in the present meta-analysis. Therefore, the use of opioids alone to improve physical function is not supported by this review; whether opioids improve the effectiveness of rehabilitative treatments for chronic pain requires further study. Opioids did not have an appreciable positive or negative effect on mood. The PGASM measure allows subjects to aggregate multiple aspects of their experience, including pain relief, improvement in physical and emotional function, side effects, and convenience, into a single measure.37 In the present meta-analysis, these measures were congruent with the primary finding that opioids are efficacious for the treatment of chronic non-cancer pain. However, it is worth noting that the forest plot (Figure 2) showed that the efficacy estimates appear heterogeneous across studies. While the reasons for this are not certain, possible reasons include differences in study design methodology, inclusion and exclusion criteria, statistical analyses, concomitant and rescue medications, dosing, and numerous other factors.

It is worth noting that AE rates in the double-blind periods were similar between study drug and placebo, with dropouts due to AEs being higher in the drug group while dropouts due to loss of efficacy were higher in the placebo group. However, because patients with significant tolerability issues during the open-label titration phase are deliberately excluded from the randomized double-blind treatment phase, AE rates in the randomized double-blind treatment phase of EERW studies do not represent rates that would occur in prospective parallel clinical trials;38 however, AE rates may be more reflective of ongoing AE rates in clinical practice, where, like in the EERW designs, patients with poor tolerability or efficacy are taken off treatment with opioids relatively early after a trial of therapy.

In a recent meta-analysis evaluating the efficacy of opioids for CLBP, the authors concluded that opioids provided “moderate short-term relief” but the effect is not clinically important.39 In that meta-analysis, Shaheed et al define “clinically important” arbitrarily as a group mean difference in pain or disability >20 points on a 0–100 scale,39 while clinical importance is more usefully viewed as a multidimensional concept that encompasses multiple factors including efficacy, safety, and availability of other treatments.40 It is worth noting that the efficacy of opioids is at least as large as that of any other treatment for chronic pain.38 Thus, requiring a group mean difference of 20 points on a 0–100 pain scale would lead to a nihilistic conclusion that no pharmacological treatments for chronic pain are useful. While the effectiveness of existing treatments for chronic pain leaves plenty of room for improvement, and considering that only a small minority of patients do not experience clinically meaningful treat-
ment responses, discarding entirely all analgesics approved for chronic pain contradicts numerous treatment guidelines, international treatment guidelines, widespread patient experience, and the FDA approval process.

These authors, as well as others, defined a 12-week treatment period as “short-term.” While 3 months is indeed short in comparison to the years patients may use opioid treatment for chronic pain, 3-month treatment periods are considered the regulatory standard for assessing long-term efficacy of a treatment in placebo-controlled clinical trials of chronic conditions. Indeed, the efficacy of all major drug and non-drug therapies for chronic pain is based on a similar body of evidence (i.e., the number of studies and duration of those studies are similar for all chronic pain treatments). Thus, the body of evidence for the efficacy of opioids is similar in terms of duration of studies to that for other approved classes of analgesics.

The 3-month trial duration is not entirely arbitrary: beyond several months, the internal validity of clinical trials tends to degrade due to dropouts, addition of concomitant treatments (permitted or not), noncompliance with treatment, and other factors. While it is desirable in theory to conduct prospective studies of longer duration, so that important complications that take time can emerge, and the durability of efficacy can be directly observed, the feasibility of and the technical requirements for such studies have not yet been addressed. Finally, the inclusion of EERW studies in our meta-analysis allows a richer interpretation of “long-term” efficacy: the EERW design is utilized to assess the efficacy of treatment that has been administered for potentially lengthy periods of time prior to randomization. This design, also called the randomized discontinuation design, has been used in multiple therapeutic areas where it is important to determine whether patients responding to long-term open-label treatment are, in fact, responding to the pharmacological effects of the drug, or just the non-specific effects of treatment (such as the placebo response). Such studies have been performed for decades in oncology, depression, rheumatoid arthritis, cardiology, schizophrenia, and numerous other indications. Therefore, the superiority after randomization of active treatment over placebo among patients who have already demonstrated a longstanding response to open-label medication can be interpreted as long-term efficacy that is not due to a placebo effect or other non-specific factors.

Many of these products have also undergone long-term open-label extension studies to provide information on the durability of treatment responses achieved during the randomized controlled trials; we did not examine these studies in this review; however they generally demonstrate that PI reductions in patients studied in randomized controlled trials remain durable for extended periods.

This meta-analysis has several limitations. First, it only included EERW studies, therefore only included results from patients who responded to opioids during the open-label titration phase. The pros and cons of the EERW design are beyond the scope of this review, and have been amply reviewed elsewhere. To summarize, the advantages of the EERW study design are that it is accepted by the FDA for registration of drug treatments, can minimize the amount of time subjects receive ineffective or poorly tolerated treatment, may offer improved assay sensitivity, and yields open-label data that may be more relevant to clinical practice than only double-blind data. Another advantage of the EERW design is that the open-label titration phase of typical EERW studies mimics clinical practice with individual titration to optimized doses, an important design feature for medications with high inter-patient variability in optimal dose and a relatively narrow therapeutic index. Perceived disadvantages to the EERW design include questions about generalizability of both efficacy and AE data, challenges in comparing outcomes to standard prospective parallel treatment designs, and more complex interpretation. An additional limitation of note is that most of the studies included in the meta-analysis focus on CLBP, which has been a frequently used model of chronic pain because of the prevalence of the condition, and hence, the practicality of conducting clinical trials.

Many of the manuscripts screened in the present analysis failed to report critical information. This necessitated requesting data from manuscript authors, a cumbersome and time-consuming process. We recommend that journals continue to refine and require minimum quality standards for proper interpretation and ease of use in meta-analyses. Initiatives like CONSORT and the EQUATOR network have been put in place to foster adequate reporting of randomized controlled trials.

Conclusion

This meta-analysis of FDA-required double-blind, randomized, placebo-controlled clinical trials of opioid analgesics for the treatment of chronic pain has shown that there is an ample evidence base supporting the efficacy of opioid analgesics for at least 3 months’ duration, a standard period for the evaluation of treatments for chronic pain and other chronic disorders. This evidence base is at least as large as that for any other class of analgesics, and analysis of responders
demonstrates clinically meaningful improvements. We have not focused on the risks of opioids, nor the risk–benefit balance, and hope that our review at least characterizes the evidence base for efficacy in order to inform these important broader discussions.

Acknowledgments
The authors would like to thank Gaelen Adam for her assistance with the literature search and Bryant Smith for teaching the authors how to use several software programs that made this meta-analysis possible. The authors would also like to thank Dr. Steven Ripa, Dr. Peter Schmidt, Mary Ma, and Linda Noa for providing missing data from studies used in this meta-analysis, and Joseph Lau for his constructive review of the manuscript. This meta-analysis used methods and software tools developed by The Center for Evidence Synthesis in Health at Brown University. Support for this research was partially provided by Analgesic Solutions and partially by the Opioid Post-Marketing Requirement Consortium (OPC), an industry working group composed of pharmaceutical companies that hold an approved New Drug Application for extended release/long-acting opioids working together at FDA’s request to conduct certain post-market required studies. The OPC includes Allergan, Plc, BioDelivery Systems International, Inc., Collegium Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Depomed, Inc., Egalet Corporation, Endo Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Mallinckrodt, Inc., Pernix Therapeutics Holdings, Inc., Pfizer Inc., Purdue Pharma, L. P., and West-Ward Pharmaceuticals Corp. Current affiliation for Diana S Meske is Collegium Pharmaceutical Inc, Canton, MA, USA.

Disclosure
Nathaniel Katz has acted as a consultant for Allergan, Plc, Collegium Pharmaceuticals, Inc., Depomed, Inc., Egalet Corporation, Endo Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Mallinckrodt, Inc., Pfizer Inc., and Purdue Pharma, L. P. Diana S Meske was employed by Analgesic Solutions when the work was completed for this manuscript, however at the time of publication she was employed by Collegium Pharmaceutical Inc. The authors report no other conflicts of interest in this work.

References


